<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05051891</url>
  </required_header>
  <id_info>
    <org_study_id>ICP-CL-00113</org_study_id>
    <nct_id>NCT05051891</nct_id>
  </id_info>
  <brief_title>A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma</brief_title>
  <official_title>A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing InnoCare Pharma Tech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing InnoCare Pharma Tech Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of orelabrutinib combined with R-CHOP vs. R-CHOP alone in the&#xD;
      treatment of treatment-naїve mantle cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2027</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>To evaluate the Progression-free Survival (PFS) by the Independent Review Committee (IRC) according to the 2014 International Working Group Criteria for Non-Hodgkin Lymphoma (iwNHL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRR</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Complete Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">356</enrollment>
  <condition>Treatment-naїve Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>the experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orelabrutinib in Combinaion with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R-CHOP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orelabrutinib and R-CHOP</intervention_name>
    <description>Orelabrutinib in Combinaion with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)</description>
    <arm_group_label>the experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-CHOP</intervention_name>
    <description>Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)</description>
    <arm_group_label>The control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 65 &lt; age &lt;80, or 60 ≤ age ≤65 and is ineligible for autologous stem cell&#xD;
             transplantation as assessed by the investigator&#xD;
&#xD;
          2. Histopathological confirmed MCL and either expression of cyclin D1 or t (11;14)&#xD;
             chromosomal translocation (in association with CD20). The verification will be based&#xD;
             on central review of the local pathology report.&#xD;
&#xD;
          3. No previous systemic treatment for MCL.&#xD;
&#xD;
          4. ECOG physical strength score is 0-2.&#xD;
&#xD;
          5. Expected survival time &gt;6 months.&#xD;
&#xD;
          6. Voluntary written informed consent prior to screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uncontrolled or significant cardiovascular diseases&#xD;
&#xD;
          2. History of stroke or intracranial hemorrhage within 6 months before first&#xD;
             administration of study treatment.&#xD;
&#xD;
          3. Any mental or cognitive impairments which may limit the subject 's understanding and&#xD;
             execution of informed consent as well as study compliance;&#xD;
&#xD;
          4. Pregnant or breastfeeding women and those who do not agree to take contraceptive&#xD;
             measures.&#xD;
&#xD;
          5. Conditions in which a potentially life-threatening illness or severe organ dysfunction&#xD;
             is not considered appropriate by the investigator.&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>April Huang</last_name>
    <phone>010-66609723</phone>
    <email>April.huang@innocarepharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xinghua Zhao</last_name>
    <email>Xinghua.zhao@innocarepharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100143</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jun Zhu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Depei Wu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>September 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

